API & finished dosage catalog
Browse 82 active ingredients, finished dosage forms and development programs, made at our own facilities or sourced through our partner network.
82 of 82 products
Narrow the catalog by therapeutic area, regulatory status, or business line.
GLP-1 & GIP actives · 3
ProductTherapeutic areaBusiness modelRegulatory status
Oligonucleotides · 10
ProductTherapeutic areaBusiness modelRegulatory status
- BepirovirseninvestigationalOwn facilityOligonucleotidesOwn facility supply
- InclisiranOwn facilityOligonucleotides · Cardiovascular & hematologyCDMOGMPDMF
- NedosiranOwn facilityOligonucleotidesOwn facility supply
- NusinersenOwn facilityOligonucleotidesCDMO
- OlezarsenOwn facilityOligonucleotidesOwn facility supply
- SalanerseninvestigationalOwn facilityOligonucleotidesOwn facility supply
- SiRNAOligonucleotidesCDMO (siRNA + ASO)
- TofersenOwn facilityOligonucleotidesOwn facility supply
- VolanesorsenOwn facilityOligonucleotidesOwn facility supply
- VutrisiranOwn facilityOligonucleotidesOwn facility supply
Longevity & Specialty Actives · 5
ProductTherapeutic areaBusiness modelRegulatory status
- DDVFOwn facility3,4-DivanillyltetrahydrofuranCAS 34730-78-4Longevity & Specialty ActivesOwn facility supply
- FAD+Own facilityCAS 146-14-5Longevity & Specialty ActivesOwn facility supply
- L-CitrullineOwn facilityCAS 372-75-8Longevity & Specialty ActivesOwn facility supply
- NAD+Own facilityLongevity & Specialty ActivesInjectable pharma grade supplyDMF on-goingNDC
- NMNOwn facilityCAS 1094-61-7Longevity & Specialty ActivesOwn facility supply
Specialty actives · 3
ProductTherapeutic areaBusiness modelRegulatory status
ADC & mAb (license-out) · 7
ProductTherapeutic areaBusiness modelRegulatory status
- Adebrelimab (PD-L1)PD-L1ADC & mAb (license-out)License-outNMPA approval
- BevacizumabADC & mAb (license-out) · Monoclonal antibodiesLicense-outNMPA approval
- Camrelizumab (PD-1)PD-1ADC & mAb (license-out)License-outNMPA approval
- RamucirumabADC & mAb (license-out) · Monoclonal antibodiesLicense-outNMPA approval
- Recaticimab (PCSK9)PCSK9ADC & mAb (license-out)License-outNMPA approval
- Trastuzumab Rezetecan (HER2 ADC)investigationalHER2 ADCADC & mAb (license-out)License-out
- VunakizumabADC & mAb (license-out)License-out
Animal health · 6
ProductTherapeutic areaBusiness modelRegulatory status
- AfoxolanerAnimal healthCDMO+API + device supplyVMF
- Atipamezole HclAnimal healthCDMO+API + device supplyVMF
- Cefovecin SodiumAnimal healthCDMO+API + device supplyVMF
- FirocoxibAnimal healthCDMO+API + device supplyVMF
- FluralanerAnimal healthCDMO+API + device supplyVMF
- OclacitinibAnimal healthCDMO+API + device supplyVMF
Antibiotics · 8
ProductTherapeutic areaBusiness modelRegulatory status
- Human Insulin/Insulin GlargineAntibioticsGMP+DMF+Tech
- LymecyclineAntibioticsAPI supply
- Meropenam CarbonateAntibioticsAPI supplyGMPDMF
- Minocycline HclAntibioticsAPI supplyNMPA approval
- Omadacycline HclAntibioticsCDMO + API supplyNMPA approval
- Sarecycline HclAntibioticsCDMO + API supplyLocal GMPGMP
- Tazobactam SodiumAntibioticsAPI supplyLocal GMPGMP
- Tigecycline HclAntibioticsGMP+DMF readyGMPDMF
Antivirals · 3
ProductTherapeutic areaBusiness modelRegulatory status
Cardiovascular & hematology · 5
ProductTherapeutic areaBusiness modelRegulatory status
- EdoxabanCardiovascular & hematologyAPI supplyLocal GMPGMP
- Eltrombopag OlamineCardiovascular & hematologyAPI supplyLocal GMPGMP
- Fingolimod HCLCardiovascular & hematologyAPI supplyLocal GMPGMP
- MilrinoneCardiovascular & hematologyAPI supplyLocal GMPGMP
- NicergolineCardiovascular & hematologyAPI supplyLocal GMPGMP
Dermatology & antifungals · 2
ProductTherapeutic areaBusiness modelRegulatory status
Hepatology · 1
ProductTherapeutic areaBusiness modelRegulatory status
Insulins · 4
ProductTherapeutic areaBusiness modelRegulatory status
Monoclonal antibodies · 3
ProductTherapeutic areaBusiness modelRegulatory status
Neurology (migraine) · 3
ProductTherapeutic areaBusiness modelRegulatory status
Oncology · 7
ProductTherapeutic areaBusiness modelRegulatory status
Respiratory · 4
ProductTherapeutic areaBusiness modelRegulatory status
Surgery · 5
ProductTherapeutic areaBusiness modelRegulatory status
Women's health · 3
ProductTherapeutic areaBusiness modelRegulatory status